Form4insider filings, from the source

SEC Form 4 · accession 0000899243-16-014620

Aimmune Therapeutics, Inc. · AIMT

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Stephen George Dilly
Officer — See Remarks · Director
Period of report
Feb 26, 2016
Accepted (ET)
Feb 26, 2016 · 7:41 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001631650

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Stock, $0.0001 par valueF1holding———765,308D
Common Stock, $0.0001 par valueF2holding———65,850IBy GRAT
Common Stock, $0.0001 par valueF3holding———65,850IBy Wife's GRAT

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (right to buy)F4$16.93Feb 26, 2016A240,000A—Feb 26, 2026Common Stock240,000240,000D

Explanation of responses

Remarks

President and Chief Executive Officer